BE RADIANT
Research type
Research Study
Full title
A Multicentre, Randomised, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis
IRAS ID
248826
Contact name
Fakhria Amiri
Contact email
Sponsor organisation
UCB Biopharma SPRL
Eudract number
2017-003784-35
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
128707, IND number
Duration of Study in the UK
2 years, 1 months, 26 days
Research summary
Psoriasis is a long-term skin disease in which the skin cells grow faster than normal causing a build-up of cells on the surface of skin. Red, raised patches of skin covered with silver-coloured scales form on the skin. The purpose of this study is to understand how safe and effective bimekizumab, the study drug is in comparison to an already approved drug called secukinumab (Cosentyx) in treating chronic plaque psoriasis. It will also help us understand how bimekizumab acts in the body, and how the body reacts to bimekizumab. Additionally, this study will also help in understanding the effect of bimekizumab on participant's general health-related wellbeing.
This is a double-blinded study, meaning neither the participant nor the study doctor will know which medication is being given. The study medication will be randomly assigned; participants will receive either bimekizumab or secukinumab.Participants in the bimekizumab group will receive placebo during the additional secukinumab dosing visits so that the treatment received remains blinded.
UCB Biopharma SPRL is the sponsor of this study which will take place worldwide. It is anticipated that approximately 700 participants will be enrolled in the study worldwide. For each participant, the study will last a maximum of 69 weeks.
REC name
London - Brent Research Ethics Committee
REC reference
18/LO/1360
Date of REC Opinion
17 Oct 2018
REC opinion
Further Information Favourable Opinion